Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Novel Aspects in Kidney Disease in Diabetes 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Aspects in Kidney Disease in Diabetes 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 9094

Special Issue Editor

Prof. Dr. Giuseppina T. Russo

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, Policlinico Universitario “G. Martino”, Via Consolare Valeria, 98124 Messina, Italy
Interests: diabetes; diabetic kidney disease; gender medicine; macrovascular disease; lipid metabolism; homocysteine; genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus (DM) affects millions of people worldwide, and ~40% of them may have diabetic nephropathy.

We are witnessing a dramatic change in the pathophysiology, management and therapeutic approach of diabetic nephropathy, now termed kidney disease associated with DM. Accumulating evidence has recently been focused on clarifying the different morphological and pathophysiological aspects of renal lesions associated with diabetes, especially the non-albuminuric phenotype. There is still an ongoing debate on the prevalence and the role of different forms of kidney disease in diabetic subjects, other than diabetic kidney disease and the potential biomarkers able to distinguish among them, when the biopsy is not feasible. Renewed hope comes from the recent evidences from experimental research, and from cardiovascular outcomes trials (CVOTs), which have demonstrated the benefits of the new classes of hypoglycemic drugs on the occurrence and progression of kidney disease as well as on cardiovascular disease (CVD) risk. Finally, the high CVD risk in DM subjects with kidney disease calls for the urgent need to translate basic research into clinical practice, in order to help people with DM to survive longer and without the specter of dialysis in front of them.

This Special Issue will deal with several aspects of diabetes and its renal complications, as specified below. We welcome original research articles, comprehensive reviews and short communications with a focus on molecular level studies.

Potential topics include, but are not limited to, the relationship between kidney disease associated with diabetes with:

1. Sex/gender differences;

2. Renal morphology changes in diabetic patients;

3. Differences between Type 1 and type 2 diabetes;

4. Role of genetics/omics

5. Predictive models/artificial intelligence;

6. New biomarkers/new applications of old biomarkers;

7. Phenotyping DKD: isolated low eGFR vs. albuminuria;

8. New approaches with albuminuria: overcoming traditional cut-offs;

9. Role of the renin–angiotensin system and SGT2i;

10. Predictors of fast progression in patients with diabetes mellitus and renal failure;

11. Role of vitamin D status in diabetic patients with renal disease;

12. Management of Diabetic Mellitus in patients with reduced renal function;

13. Oxidative stress/endothelial dysfunction/inflammation and the progression of diabetic nephropathy;

14. Potential beneficial effects of SGTL2 inhibitors and GLP1-RAs and/or their combination;

15. Mineral corticoid receptor antagonist and diabetes mellitus;

16. Ageing, kidney and diabetes management;

17. Cardiovascular risk factors and diabetic kidney;

18. Nutritional aspects in diabetic patients with chronic renal failure.

Prof. Dr. Giuseppina T. Russo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic kidney disease
  • microalbuminuria
  • gender
  • genetics, omics, artificial intelligence, biomarkers
  • low protein diet in diabetic nephropathy
  • ageing
  • sglt2
  • glp1-ras

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3505 KiB  
Article
Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells
by Mohammed F. Gholam, Lauren P. Liu, Louis A. Searcy, Nancy D. Denslow and Abdel A. Alli
Int. J. Mol. Sci. 2023, 24(2), 1408; https://doi.org/10.3390/ijms24021408 - 11 Jan 2023
Cited by 5 | Viewed by 1891
Abstract
In addition to inhibiting renal glucose reabsorption and allowing for glucose excretion, the sodium/glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin may be efficacious in treating various comorbidities associated with type 2 diabetes mellitus (T2DM). The molecular mechanisms by which dapagliflozin exerts its beneficial effects [...] Read more.
In addition to inhibiting renal glucose reabsorption and allowing for glucose excretion, the sodium/glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin may be efficacious in treating various comorbidities associated with type 2 diabetes mellitus (T2DM). The molecular mechanisms by which dapagliflozin exerts its beneficial effects are largely unknown. We hypothesized dapagliflozin treatment in the diabetic kidney alters plasma membrane lipid composition, suppresses extracellular vesicle (EV) release from kidney cells, and disrupts lipid rafts in proximal tubule cells. In order to test this hypothesis, we treated diabetic db/db mice with dapagliflozin (N = 8) or vehicle (N = 8) and performed mass spectrometry-based lipidomics to investigate changes in the concentrations of membrane lipids in the kidney cortex. In addition, we isolated urinary EVs (uEVs) from urine samples collected during the active phase and the inactive phase of the mice and then probed for changes in membrane proteins enriched in the EVs. Multiple triacylglycerols (TAGs) were enriched in the kidney cortex membrane fractions of vehicle-treated diabetic db/db mice, while the levels of multiple phosphatidylethanolamines were significantly higher in similar mice treated with dapagliflozin. EV concentration and size were lesser in the urine samples collected during the inactive phase of dapagliflozin-treated diabetic mice. In cultured mouse proximal tubule cells treated with dapagliflozin, the lipid raft protein caveolin-1 shifted from less dense fractions to more dense sucrose density gradient fractions. Taken together, these results suggest dapagliflozin may regulate lipid-mediated signal transduction in the diabetic kidney. Full article
(This article belongs to the Special Issue Novel Aspects in Kidney Disease in Diabetes 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 965 KiB  
Review
Vitamin D and Diabetic Kidney Disease
by Ho-Yin Huang, Ting-Wei Lin, Zi-Xuan Hong and Lee-Moay Lim
Int. J. Mol. Sci. 2023, 24(4), 3751; https://doi.org/10.3390/ijms24043751 - 13 Feb 2023
Cited by 10 | Viewed by 3605
Abstract
Vitamin D is a hormone involved in many physiological processes. Its active form, 1,25(OH)2D3, modulates serum calcium–phosphate homeostasis and skeletal homeostasis. A growing body of evidence has demonstrated the renoprotective effects of vitamin D. Vitamin D modulates endothelial function, [...] Read more.
Vitamin D is a hormone involved in many physiological processes. Its active form, 1,25(OH)2D3, modulates serum calcium–phosphate homeostasis and skeletal homeostasis. A growing body of evidence has demonstrated the renoprotective effects of vitamin D. Vitamin D modulates endothelial function, is associated with podocyte preservation, regulates the renin–angiotensin–aldosterone system, and has anti-inflammatory effects. Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease worldwide. There are numerous studies supporting vitamin D as a renoprotector, potentially delaying the onset of DKD. This review summarizes the findings of current research on vitamin D and its role in DKD. Full article
(This article belongs to the Special Issue Novel Aspects in Kidney Disease in Diabetes 2.0)
►▼ Show Figures

Figure 1

11 pages, 433 KiB  
Review
Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease
by Christodoula Kourtidou, Maria Stangou, Smaragdi Marinaki and Konstantinos Tziomalos
Int. J. Mol. Sci. 2021, 22(20), 11196; https://doi.org/10.3390/ijms222011196 - 17 Oct 2021
Cited by 9 | Viewed by 2865
Abstract
Patients with diabetic kidney disease (DKD) are at very high risk for cardiovascular events. Only part of this increased risk can be attributed to the presence of diabetes mellitus (DM) and to other DM-related comorbidities, including hypertension and obesity. The identification of novel [...] Read more.
Patients with diabetic kidney disease (DKD) are at very high risk for cardiovascular events. Only part of this increased risk can be attributed to the presence of diabetes mellitus (DM) and to other DM-related comorbidities, including hypertension and obesity. The identification of novel risk factors that underpin the association between DKD and cardiovascular disease (CVD) is essential for risk stratification, for individualization of treatment and for identification of novel treatment targets.In the present review, we summarize the current knowledge regarding the role of emerging cardiovascular risk markers in patients with DKD. Among these biomarkers, fibroblast growth factor-23 and copeptin were studied more extensively and consistently predicted cardiovascular events in this population. Therefore, it might be useful to incorporate them in risk stratification strategies in patients with DKD to identify those who would possibly benefit from more aggressive management of cardiovascular risk factors. Full article
(This article belongs to the Special Issue Novel Aspects in Kidney Disease in Diabetes 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop